Medchem Pyronaridine tetraphosphate 99.69%

Pyronaridine tetraphosphate is an orally active Mannich base anti-malarial agent that demonstrates strong efficacy against Plasmodium falciparum (the parasite responsible for malaria) and Echinococcus granulosus (a parasitic infection causing hydatid disease). This compound is primarily used for research purposes and shows potential in malaria treatment and parasitic infections. The 99.69% purity of Pyronaridine tetraphosphate ensures its effectiveness in high-precision studies, including in vitro assays and animal model research.

Chemical Identifiers

• CAS Number: 76748-86-2
• IUPAC Name: 2-(dibutylamino)-1-[(9Z)-2,7-dichloro-9-[(4-chlorophenyl)methylidene]-9H-fluoren-4-yl]ethan-1-ol
• Molecular Formula: C29H44ClN5O18P4
• Molecular Weight: 910.03 g/mol
• SMILES: OC1=C(CN2CCCC2)C=C(NC3=C4N=C(OC)C=CC4=NC5=CC(Cl)=CC=C53)C=C1CN6CCCC6.O=P(O)(O)O.O=P(O)(O)O.O=P(O)(O)O.O=P(O)(O)O

Key Features and Benefits

• High Purity (99.69%):
  Pyronaridine tetraphosphate 99.69% provides a highly purified form of the anti-malarial agent, ensuring precise dosages and effective results in both in vitro and in vivo experiments.
• Effective Against Malaria:
  Pyronaridine tetraphosphate is used to treat Plasmodium falciparum infections, a primary cause of malaria. In in vitro studies, it shows IC50 values as low as 1.53-3.94 nM, indicating its potent activity against malaria parasites.
• Activity Against Echinococcus Granulosus:
  In animal models, Pyronaridine tetraphosphate demonstrated the ability to reduce parasitic burden and successfully treat Echinococcus granulosus infection, a parasitic disease caused by the tapeworm Echinococcus.
• In Vivo Efficacy:
  The compound has shown reduced parasitic weight and effective clearance of secondary infections (cysts) in Echinococcus granulosus-infected mice, with significant parasite reduction observed after oral administration of 57 mg/kg for 30 days.
• Convenient for Research:
  Pyronaridine tetraphosphate is delivered as a solid with excellent stability, ideal for research use in malaria treatment studies and parasitic disease research.
• Broad Use in Malaria Research:
  This compound is also involved in several clinical trials for malaria treatment, including ongoing Phase 2 and Phase 3 trials that evaluate its efficacy against Plasmodium falciparum.

Applications

Pyronaridine tetraphosphate is mainly used in the following research applications:

• Malaria Treatment Studies:
  Widely used for studying malaria treatment, particularly in combination with artemisinin-based therapies (ACTs). It helps researchers evaluate drug efficacy against Plasmodium falciparum and other related parasites.
• Parasitic Disease Research:
  Utilized in Echinococcus granulosus-infected animal models to study drug effects on hydatid disease and investigate potential therapies for cystic echinococcosis.
• In Vitro Assays:
  Ideal for cell viability assays and parasite culture experiments to measure the anti-parasitic effects of Pyronaridine tetraphosphate.
• Screening for Malaria Inhibitors:
  Used in screening compounds that could serve as anti-malarial drugs, particularly targeting Plasmodium falciparum and Echinococcus granulosus.

In Vitro Data

• Cell Viability Assay (P. falciparum):
  • Cell Lines: P. falciparum: 3D7, K1, VS1, FCB, TM90C2a, FCR3
  • Concentration: 0-7 nM
  • Incubation Time: 24 hours
  • Result:
    • IC50 values ranging from 1.53 nM to 3.94 nM across different strains of Plasmodium falciparum.

In Vivo Data

• Echinococcus Granulosus-Infected Mice Model:
  • Dosage: 57 mg/kg (oral, once daily for 30 days)
  • Result:
    • 42.4% reduction in parasite wet weight
    • 90.7% reduction in secondary infection (cysts)
• Intraperitoneal Injection (Single Dose):
  • Result:
    • Higher exposure in liver than in plasma in male ICR mice, indicating effective liver distribution.

Storage and Handling

• Storage:
  Store Pyronaridine tetraphosphate at 4°C, sealed, and away from moisture for long-term stability. In solution, store at -80°C for six months, and -20°C for one month.
• Handling:
  Protective gloves and eye protection should be worn when handling this compound, and it should be used in accordance with lab safety protocols.

Certifications

• This product is for research use only and not for therapeutic or diagnostic applications.

Pyronaridine tetraphosphate 99.69% is a potent, orally active anti-malarial agent used in malaria research and parasitic disease studies. Its high efficacy against Plasmodium falciparum and Echinococcus granulosus, combined with its in vitro and in vivo effectiveness, makes it a valuable tool for drug development and malaria treatment. Its high purity, stable formulation, and effective dosing in animal models make it an excellent choice for researchers studying malaria and parasitic infections.